SEC Form 4 · Updated Daily
CBIO
— Crescent Biopharma, Inc. OwnershipInsider and institutional ownership derived from SEC Form 4 filings. Click any owner to see their holdings across every company they’ve filed on, and how their position has changed over time.
Current Reporting Owners
| Owner | Role | Shares Owned | As Of | Last Activity |
|---|---|---|---|---|
| Harwin Peter Evan | Director | 3,601,316 | 2026-07-16 | P |
| Fairmount Healthcare Fund II L.P. | Director | 3,601,316 | 2026-07-16 | P |
| Fairmount Funds Management LLC | Director | 3,601,316 | 2026-07-16 | P |
| Kiselak Tomas | Director | 3,601,316 | 2026-07-16 | P |
| Brumm Joshua T | Director · Officer | 281,212 | 2026-06-22 | S |
| McNeill Jonathan | Officer | 139,158 | 2026-06-22 | S |
| BIOTECHNOLOGY VALUE FUND L P | 10%+ Owner | 62,383 | 2025-06-13 | J |
| BVF PARTNERS L P/IL | 10%+ Owner | 62,383 | 2025-06-13 | J |
| BVF INC/IL | 10%+ Owner | 62,383 | 2025-06-13 | J |
| BIOTECHNOLOGY VALUE FUND II LP | Reporting Owner | 62,383 | 2025-06-13 | J |
| LAMPERT MARK N | 10%+ Owner | 62,383 | 2025-06-13 | J |
| Biotechnology Value Trading Fund OS LP | Reporting Owner | 62,383 | 2025-06-13 | J |
| BVF Partners OS Ltd. | Reporting Owner | 62,383 | 2025-06-13 | J |
| BVF I GP LLC | 10%+ Owner | 62,383 | 2025-06-13 | J |
| BVF II GP LLC | Reporting Owner | 62,383 | 2025-06-13 | J |
| BVF GP HOLDINGS LLC | 10%+ Owner | 62,383 | 2025-06-13 | J |
| Doughty Christopher Grant | Officer | 62,194 | 2025-12-15 | A |
| Pinkas Jan | Officer | 22,239 | 2026-06-22 | S |
| Im Ellie Eunkyung | Officer | 22,069 | 2026-06-22 | S |
| Scalzo Richard William | Officer | 20,298 | 2026-06-22 | S |
| Bispham Barbara Harlin | Officer | 19,330 | 2026-06-22 | S |
| Lynch Ryan | Officer | 13,871 | 2026-06-22 | S |
Recent Filings
| Date | Owner | Activity | Shares | Price | Owned After |
|---|---|---|---|---|---|
| 2026-07-16 | Harwin Peter Evan | Open-market buy (derivative) | 525,897 | $14.50 | 2,294,037 |
| 2026-07-16 | Harwin Peter Evan | Open-market buy | 853,450 | $14.50 | 3,601,316 |
| 2026-07-16 | Kiselak Tomas | Open-market buy (derivative) | 525,897 | $14.50 | 2,294,037 |
| 2026-07-16 | Kiselak Tomas | Open-market buy | 853,450 | $14.50 | 3,601,316 |
| 2026-07-16 | Fairmount Healthcare Fund II L.P. | Open-market buy (derivative) | 525,897 | $14.50 | 2,294,037 |
| 2026-07-16 | Fairmount Healthcare Fund II L.P. | Open-market buy | 853,450 | $14.50 | 3,601,316 |
| 2026-07-16 | Fairmount Funds Management LLC | Open-market buy (derivative) | 525,897 | $14.50 | 2,294,037 |
| 2026-07-16 | Fairmount Funds Management LLC | Open-market buy | 853,450 | $14.50 | 3,601,316 |
| 2026-06-22 | Brumm Joshua T | Open-market sale | 42,305 | $17.99 | 281,212 |
| 2026-06-22 | McNeill Jonathan | Open-market sale | 20,549 | $17.99 | 139,158 |
| 2026-06-22 | Im Ellie Eunkyung | Open-market sale | 1,219 | $17.99 | 22,069 |
| 2026-06-22 | Bispham Barbara Harlin | Open-market sale | 1,218 | $17.99 | 19,330 |
| 2026-06-22 | Scalzo Richard William | Open-market sale | 1,112 | $17.99 | 20,298 |
| 2026-06-22 | Pinkas Jan | Open-market sale | 1,288 | $17.99 | 22,239 |
| 2026-06-22 | Lynch Ryan | Open-market sale | 465 | $17.99 | 13,871 |
| 2026-06-02 | Kiselak Tomas | Grant / award (derivative) | 11,050 | $0.00 | 11,050 |
| 2026-06-02 | Harwin Peter Evan | Grant / award (derivative) | 11,050 | $0.00 | 11,050 |
| 2026-06-02 | Fairmount Healthcare Fund II L.P. | Grant / award (derivative) | 11,050 | $0.00 | 11,050 |
| 2026-06-02 | Fairmount Funds Management LLC | Grant / award (derivative) | 11,050 | $0.00 | 11,050 |
| 2026-06-02 | Moran Susan | Grant / award (derivative) | 11,050 | $0.00 | 11,050 |
| 2026-06-02 | Balcom Alexandra | Grant / award (derivative) | 11,050 | $0.00 | 11,050 |
| 2026-06-02 | Lubner David Charles | Grant / award (derivative) | 11,050 | $0.00 | 11,050 |
| 2026-06-02 | Violin Jonathan | Grant / award (derivative) | 11,050 | $0.00 | 11,050 |
| 2025-12-15 | Bispham Barbara Harlin | Grant / award (derivative) | 72,185 | $0.00 | 72,185 |
| 2025-12-15 | Bispham Barbara Harlin | Grant / award | 6,000 | — | 18,422 |
| 2025-12-15 | Bispham Barbara Harlin | Grant / award | 12,422 | — | 12,422 |
| 2025-12-15 | Lynch Ryan | Grant / award (derivative) | 33,512 | $0.00 | 33,512 |
| 2025-12-15 | Lynch Ryan | Grant / award | 4,000 | — | 12,378 |
| 2025-12-15 | Lynch Ryan | Grant / award | 8,378 | — | 8,378 |
| 2025-12-15 | Im Ellie Eunkyung | Grant / award (derivative) | 65,190 | $0.00 | 65,190 |
| 2025-12-15 | Im Ellie Eunkyung | Grant / award | 5,000 | — | 21,298 |
| 2025-12-15 | Im Ellie Eunkyung | Grant / award | 16,298 | — | 16,298 |
| 2025-12-15 | McNeill Jonathan | Grant / award (derivative) | 78,029 | $0.00 | 78,029 |
| 2025-12-15 | McNeill Jonathan | Grant / award | 6,000 | — | 159,707 |
| 2025-12-15 | McNeill Jonathan | Grant / award | 19,507 | — | 153,707 |
| 2025-12-15 | Scalzo Richard William | Grant / award (derivative) | 57,688 | $0.00 | 57,688 |
| 2025-12-15 | Scalzo Richard William | Grant / award | 5,000 | — | 19,422 |
| 2025-12-15 | Scalzo Richard William | Grant / award | 14,422 | — | 14,422 |
| 2025-12-15 | Brumm Joshua T | Grant / award (derivative) | 180,467 | $0.00 | 180,467 |
| 2025-12-15 | Brumm Joshua T | Grant / award | 10,000 | — | 323,517 |
Source: SEC EDGAR Form 4 filings. For informational purposes only — not investment advice.